Pharmaceuticals - Community Register

  

Community register of veterinary medicinal products


AUTHORISED  

Product information

Invented name: Rhiniseng   
Auth. number : EU/2/10/109
INN : inactivated vaccine against atrophic rhinitis in pigs
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI09 - Immunologicals for suidae
Pharmacological subgroup: QI09A - Pig
Chemical subgroup: QI09AB - Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)
Chemical substance: QI09AB04 - Bordetella + pasteurella
(See WHO ATCvet Index)
Indication: For the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with Bordetella bronchiseptica and Pasteurella multocida infections during the fattening period
Marketing Authorisation Holder: Laboratorios Hipra, S.A.
Avda. La Selva, 135, E-17170- Amer (Girona), España

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/09/2010 Centralised - Authorisation EMEA/V/C/160 (2010)6439 of 16/09/2010
23/11/2010 Corrigendum (2010)8323 corr of 22/11/2010